Elismetrep for fast relief of migraine attacks
Part of Brain & nervous system clinical trials.
This trial tests a new oral medication called elismetrep (K-304) for quickly stopping migraine pain and other symptoms. If you have regular migraines, this could offer a new option that works fast when a migraine starts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old.
- Have had migraines for more than 1 year, with or without aura.
- Have 2–10 moderate or severe migraine attacks per month in the last 2 months.
- Have a personal smartphone to download the study eDiary app.
- If you're a woman who can get pregnant, you must agree to use birth control or stay abstinent during the trial.
- Not be pregnant, breastfeeding, or have certain medical conditions (like heart disease, HIV, hepatitis, or recent stomach surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, MEDI0618, against a placebo for people with episodic migraine. The goal is to see if MEDI0618 is safe and effective at reducing migraine days.
This study tests an investigational medicine called elismetrep (K-304) for treating migraine attacks quickly. If you have migraines, you take the medicine when a migraine starts and report how well it works.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
This study tests an add-on migraine medicine (eptinezumab) given in the emergency room to quickly relieve a migraine attack, in addition to the usual care. It aims to see if this approach reduces pain and prevents the migraine from coming back.
This trial tests if a gentle nasal stimulation device can help prevent migraines. It is for adults with frequent migraines (at least 8 days per month).
This trial tests if eptinezumab can stop a migraine attack that is already happening. It may help people who get migraines often and are already part of the TACHIS study.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.